Measurement of newly developed tumor markers and molecular markers in health screening for lung cancer

为了建立早期诊断肺癌的血清标志物，我们开发了检测候选分子标志物的方法。此外，我们进行了大规模的调查，以确认该标志物结合已知的肿瘤标志物在健康人群中检测肺癌的性能。首先，我们建立了酶联免疫吸附试验（ELISA）来检测可溶性ULBP-2。该ELISA系统能检测到肺癌患者血清中ULBP-2的升高，而在正常志愿者中检测不到。这些结果表明ELISA系统的有效性。其次，为了研究分子和肿瘤标志物在肺癌健康筛查中的作用，我们招募了健康志愿者进行群体健康检查。我们分别测量了ProGRP、ULBP-2、抗p53自身抗体和可替宁作为小细胞肺癌、非小细胞肺癌、肺癌和吸烟习惯的标志物。因此，我们发现这些标记是独立的指标。第三，我们开发了一个新的招聘系统，以获取参与者的完整个人信息。我们有163个新参与者使用这个系统。2例血清ProGRP升高（- 20.0 pg/mL），但未超过正常水平（46.0 pg/mL）。血清ULBP-2轻度（2 - 10ng /ml）、中度（10 - 100ng /ml）和重度(？100 ng/ml)分别在5名、3名和1名受试者中升高。我们正计划对该研究人群进行随访，以发现肺癌的发病情况。综上所述，在本项资助的支持下，我们建立了一种检测肺癌潜在候选分子标志物的灵敏方法，并验证了其与kwon tumor maker和自身抗体联合用于癌症筛查的有效性。此外，我们开发了一种新的大规模调查系统，以确认他们在健康筛查环境中的表现。我们相信这将导致新的血清指标的发展，用于肺癌的早期检测。

To establish serum markers for early diagnosis of lung cancer, we developed methods to detect a candidate for molecular marker. In addition, we conducted a large scale survey to confirm the performance of this marker in combination with known tumor markers, to detect lung cancer among healthy people. First, we developed Enzyme-Linked Immunosorbent Assay (ELISA) for detecting soluble ULBP-2. This ELISA system could detect elevated ULBP-2 in serum of lung cancer patients, but not in normal volunteers. These results indicated the usefulness of the ELISA systems. Secondly, to study the performance of the molecular and tumor markers in health screening for lung cancer, we recruited healthy volunteers in group health examination settings. We measured ProGRP, ULBP-2, anti-p53 autoantibody, and cotinine as a marker for small cell lung cancer, non-small cell lung cancer, lung cancer, and smoking habits, respectively. As a result, we revealed that these markers are independent indicators. Thirdly, we developed a new recruitment system to obtain complete personal information of the participants. We got 163 new participants using this system. Serum ProGRP was elevated in two (?20.0 pg/mL), but not exceed a normal level (46.0 pg/mL). Serum ULBP-2 was mildly (2 - 10 ng/ml), moderately (10 - 100 ng/ml), or highly (?100 ng/ml) elevated in five, three, or one subjects, respectively. We are planning to follow up this study population to find the onsets of lung cancer. In summary, supported by this grant, we made a sensitive method to detect a potential candidate of the molecular marker of lung cancer, verified the usefulness of it in combination with kwon tumor maker and autoantibody in cancer screening. In addition, we developed a new system of mass survey to confirm their performance in health screening settings. We believe this will lead to the development of new serum indicators for early detection of lung cancer.